Every IGF-1 LR3 Question Answered, in 16 Studies

16 referenced articles

• What Is IGF-1 LR3? Why It Is a Protein, Not a Peptide4 sources
• Eighty-Three Residues, and What That Changes4 sources
• Two Receptors Close Enough to Form Hybrids3 sources
• Two Hormones, One Feedback Loop3 sources
• A Regulatory System, Deliberately Evaded4 sources
• A Strong Rationale That Did Not Translate3 sources
• A Natural Experiment in Absent IGF-13 sources
• IGF-1 LR3 Regulatory Status4 sources
• IGF-1 LR3 and Anti-Doping Status3 sources
• How to Verify a Protein With No PubChem Record3 sources
• IGF-1 LR3 Storage: A Folded Protein, Not a Peptide3 sources
• Why LR3 Exists: The Cell Culture Application3 sources
• IGF-1 LR3 Against the Native Hormone4 sources
• Recombinant Versus Synthetic: Two Different Quality Problems3 sources
• IGF-1 LR3 Structure: Three Disulfides and Why They Matter3 sources
• IGF Binding Proteins and the Free Fraction3 sources

Open research questions

• What do the Long and R3 in the name actually refer to?
• Why was IGF-1 LR3 engineered to escape binding proteins?
• How does a recombinant protein's impurity profile differ from a synthetic peptide's?
• Why can mass spectrometry not detect a misfolded protein?
• Is IGF-1 LR3 the same as the approved medicine mecasermin?
• What does WADA class S2 cover and why does it include analogues?

Deep dive: the design that runs backwards from everything else here

Almost every engineered compound in this catalogue solves the same problem in the same direction. Semaglutide attaches a C18 diacid, retatrutide and tirzepatide a C20, all to bind serum albumin and extend duration. CJC-1295's DAC goes further and binds albumin covalently at Cys34. The strategy throughout is to add binding, so the molecule survives longer in circulation. IGF-1 LR3 does the reverse. Its two modifications - arginine replacing glutamate at position 3, and a thirteen-residue N-terminal extension - exist to REMOVE binding, specifically to the IGF binding proteins that sequester the overwhelming majority of circulating IGF-1 in a ternary complex with IGFBP-3 and the acid-labile subunit. Same bound-free equilibrium, engineered in the opposite direction. The reason is that the two families face opposite constraints: an incretin peptide is cleared too fast to be useful, while IGF-1 is held too tightly to be available. Baxter's 1994 review in Hormone Research is the standard account of just how tightly.

Deep dive: a certificate written for the wrong failure mode

This is a recombinant protein, and it fails differently from everything else on this site. A synthetic peptide accumulates deletion sequences, because each coupling is slightly less than complete - at 99% efficiency a 39-mer finishes around 68% full-length, and those impurities differ by one residue's mass and show up in a mass spectrum. Ribosomal synthesis does not fail that way at all; a host cell builds the protein correctly or not at all. What contaminates the product instead is everything else the cell contained: host cell proteins, host DNA, and in bacterial systems endotoxin, which is not a protein, does not appear in a protein purity figure, and needs its own assay entirely. Layered on top is a failure mode with no peptide equivalent. This protein has three disulfide bonds, meaning six cysteines that can pair fifteen ways of which one is correct - and Milner and colleagues showed in the Biochemical Journal in 1995 that B-domain mutations influence oxidative folding, which is directly relevant since position 3 sits in the B-domain. A misfolded isomer has identical mass, identical composition, and is invisible to mass spectrometry. A certificate reading exactly like a synthetic peptide's is testing for problems this production route does not have while missing the ones it does.

Deep dive: an approved relative, and why that raises the risk rather than lowering it

Unusually for this catalogue, a licensed IGF-1 medicine exists. Mecasermin, marketed as Increlex, is recombinant human IGF-1 with an FDA label and a subcutaneous route, used in severe primary IGF-1 deficiency - Petriczko and colleagues reported on it in 2019 and Denaite and colleagues in Frontiers in Pediatrics in 2024. That is a real approval with real clinical evidence. It covers the native seventy-residue hormone. LR3 is an eighty-three-residue engineered analogue whose defining feature is deliberately altered binding behaviour, holds no marketing authorisation anywhere, and has essentially no primary literature under its own name - searches for IGF-1 LR3 and Long R3 IGF-1 return nothing. A nearby approval invites the inference that the analogue is somehow covered by it, and that inference is the most consequential error available in this category. Separately and unconditionally: IGF-1 and its analogues sit in WADA class S2, prohibited at all times, with the list extending to related substances and mimetics precisely so that structural modification creates no exemption.

Handling checklist

• Expect no PubChem record - proteins are indexed in UniProt (native IGF-1 is P05019)
• Read the certificate for host cell protein, host DNA and endotoxin, not deletion sequences
• Understand that mass spectrometry cannot detect a misfolded disulfide isomer
• Treat loss of fold as the principal failure mode - it leaves mass unchanged
• Avoid shaking and foaming; interfaces unfold proteins and aggregation is irreversible
• Use low-binding consumables; adsorption is significant at microgram quantities
• Aliquot before freezing - freeze-thaw is worse for a folded protein than a short peptide

Common mistakes

Reading mecasermin's approval as covering IGF-1 LR3

Increlex is native 70-residue rhIGF-1. LR3 is an 83-residue engineered analogue with altered binding, unlicensed everywhere. The approval does not transfer.

Expecting a synthetic-peptide certificate for a recombinant protein

There are no deletion sequences here. The relevant tests are host cell protein, host DNA, endotoxin and something addressing conformation.

Treating a clean mass spectrum as proof the protein is intact

A misfolded disulfide isomer has identical mass and composition. Only an activity or conformational assay addresses folding.

Assuming absence from PubChem is a red flag

It is expected for a protein of this size - PubChem indexes small molecules, UniProt indexes proteins. This is unlike retatrutide, where absence is genuinely odd.

Reading the cell-culture rationale as transferable

Bypassing IGFBP regulation is useful in a dish, where it is an experimental nuisance. In an organism the same system regulates a growth factor acting on nearly every tissue.